SecBot SecBot
Biotech Drug Report Generated Nov 17, 2026

Cortrophin Gel

ANIP·ANI PHARMACEUTICALS INC
BULLISH
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available since January 2022.
Why 4/10
Cortrophin Gel is already FDA-approved and commercially marketed with no pending regulatory decision (PDUFA, AdComm, or pivotal readout) in the next 12 months. The defining binary catalyst has passed. The next hard catalyst is the Q4 2026 earnings report (expected early February 2027) for commercial revenue metrics, but quarterly sales results are not a binary regulatory catalyst. Per the rubric, an approved drug with no pending regulatory decision scores 3-5; Cortrophin is ANIP's largest product (~45% of revenue) but the company also has generics, ILUVIEN, and the Egetis acquisition diversifying the thesis, so a score of 4 is appropriate.
Actionable Insight BULLISH

Cortrophin Gel is already approved and commercialized with no pending regulatory binary. The key near-term catalysts are commercial execution metrics: Q4 2026 Cortrophin revenue (expected early Feb 2027) will show whether the specialty pharmacy capacity constraints that slowed Q3 conversion have resolved, and whether the gout sales force expansion is gaining traction. The Egetis/EMCITATE acquisition acceptance period (Nov 20-Dec 18, 2026) is a separate corporate event that could affect ANIP's balance sheet and rare disease strategy.

Price Chart

Loading chart...

Executive Summary

Cortrophin Gel (Purified Cortrophin Gel, repository corticotropin injection) is an FDA-approved adrenocorticotropic hormone (ACTH) therapy for multiple chronic autoimmune disorders, marketed by ANI Pharmaceuticals (Nasdaq: ANIP). It is the only FDA-approved purified corticotropin product and competes with Mallinckrodt's Acthar Gel in a market driven by chronic autoimmune indications including multiple sclerosis exacerbations, rheumatoid arthritis, and acute gouty arthritis flares. Cortrophin Gel is ANIP's largest product, generating $138.7M in Q3 2026 (+36% YoY) and guided at $480M-$500M for full-year 2026, representing roughly 45% of total company revenue. The drug is already approved and commercially launched, so there is no pending FDA binary catalyst; the investor focus is on commercial execution, gout expansion, and specialty pharmacy capacity.

How It Works

Cortrophin Gel is a purified form of adrenocorticotropic hormone (ACTH), a naturally occurring hormone that stimulates the adrenal glands to release cortisol and other steroid hormones. This broad anti-inflammatory and immunosuppressive effect makes it useful for treating a range of autoimmune and inflammatory conditions. Unlike synthetic steroids, ACTH also acts on melanocortin receptors throughout the body, which may provide additional anti-inflammatory benefits through non-steroid pathways.

Trial Status

Cortrophin Gel was originally FDA-approved decades ago (original NDA 008975 approved 1954). ANI Pharmaceuticals launched the product commercially in January 2022. The FDA granted supplemental approvals for a 1-mL vial size for acute gout (October 2023), a prefilled syringe format (March 2025), and a labeling update (October 2026). No pivotal clinical trials are ongoing for new indications; the company is pursuing commercial expansion into gout via sales force deployment rather than new clinical data.

The Two-Sided Case

▲ Bull Case5
Cortrophin Gel is ANIP's largest and fastest-growing product: Q3 2026 revenue of $138.7M was up 36% YoY and 18% QoQ, with full-year 2026 guidance of $480M-$500M (38-44% YoY growth).
The drug is the only FDA-approved purified corticotropin product, competing in a market with limited alternatives (primarily Mallinckrodt's Acthar Gel), giving ANIP pricing power and a sticky chronic-use patient base.
ANI is expanding into the acute gout indication with a dedicated sales force, which could open a large new patient population and drive further growth.
Analyst consensus is bullish: 12 of 15 analysts rate ANIP Buy or Strong Buy, with a mean price target of $103.38 (45.8% upside from the current ~$70.89).
The company has strong institutional support: BlackRock ($229M), American Century (doubled position to $66M), and UBS (doubled to $45M) are major holders as of Q3 2026.
▼ Bear Case6
Cortrophin Gel revenue guidance was cut in August 2026 from $540M-$575M to $520M-$540M, and then narrowed further to $480M-$500M by November 2026, signaling demand or conversion headwinds.
Q3 2026 revenue conversion was slower than expected due to specialty pharmacy capacity constraints, suggesting operational bottlenecks that could persist.
The drug faces potential competition from Acthar Gel (Mallinckrodt), and any generic or biosimilar entry could erode pricing.
ANI's pending $560M acquisition of Egetis Therapeutics adds debt and integration risk; the bridge facility is a 364-day loan that needs refinancing.
Insiders including the CEO (Nikhil Lalwani, $388K sold), CFO (Stephen Carey, $208K sold), and General Counsel have been consistent sellers under 10b5-1 plans throughout 2026.
Several institutional holders trimmed or exited in Q3 2026, including Millennium Management (trimmed 52%), JPMorgan (trimmed 66%), and Rubric Capital (fully exited).

Upcoming Catalysts

  • Q4 2026 earnings report (expected early February 2027): Cortrophin Gel revenue and gout expansion metrics will be key.
  • Egetis Therapeutics tender offer acceptance period (Nov 20 - Dec 18, 2026): if 90% acceptance threshold is met, the acquisition closes around Dec 29, 2026, adding EMCITATE to the rare disease portfolio.
  • Gout sales force expansion: continued monitoring of new prescriber adoption and patient starts in the acute gout indication.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ANI PHARMACEUTICALS INC 8-K ANIP ·Originating report

Sources · 10

Hover a chip for the title
1 businesswire.com2 ksn.com3 nasdaq.com4 marketwatch.com5 msn.com6 msn.com7 seekingalpha.com8 markets.businessinsider.com9 sec.gov10 accessdata.fda.gov